My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

126.52 -0.66 (-0.52%)

Streaming Delayed Price Updated: 2:54 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

68 69 Next >

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

Via MarketBeat

Topics ETFs

A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene

December 07, 2023

Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

A Look Into Gilead Sciences Inc's Price Over Earnings ↗

December 07, 2023

Via Benzinga

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗

December 07, 2023

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Via InvestorPlace

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today ↗

December 06, 2023

Via Benzinga

Looking Into Gilead Sciences's Recent Short Interest ↗

November 22, 2023

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today ↗

November 21, 2023

Via Benzinga

Is NASDAQ:GILD suited for dividend investing? ↗

November 20, 2023

Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD).

Via Chartmill

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Via InvestorPlace

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

November 30, 2023

From Gilead Sciences, Inc.

Via Business Wire

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

November 30, 2023

These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.

Via The Motley Fool

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗

November 29, 2023

Tuesday, the FDA said it received reports of patients developing T-cell malig

Via Benzinga

J&J, Gilead, BMS: A look at undervalued dividend payers

November 29, 2023

J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown

Via MarketBeat

Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗

November 15, 2023

Via Benzinga

A Closer Look at Gilead Sciences's Options Market Dynamics ↗

November 09, 2023

Via Benzinga

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later ↗

November 26, 2023

There's no time like the present to buy these stocks.

Via The Motley Fool

Stocks Stall On November 21, 2023, As Systematic Flows Abate ↗

November 21, 2023

Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied

Via Talk Markets

FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug ↗

November 17, 2023

FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative...

Via Benzinga

In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals. ↗

November 17, 2023

GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying.

Via Chartmill

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead ↗

November 15, 2023

The companies will work together on treatments for multiple myeloma and lymphomas.

Via Investor's Business Daily

Where Gilead Sciences Stands With Analysts ↗

November 09, 2023

Via Benzinga

Kite and Arcellx Announce Expansion in Strategic Partnership

November 15, 2023

From Gilead Sciences, Inc.

Via Business Wire

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗

November 10, 2023

The major indexes ended long win streaks. Datadog led earnings winners.

Via Investor's Business Daily

Buying the dip in high-yield Gilead Sciences

November 09, 2023

Pharma stock Gilead Sciences is well-positioned for the next few years with a growing core business, a healthy pipeline, and cash flow to sustain capital return

Via MarketBeat

Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance

November 09, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Gilead Sciences to Present at Upcoming Investor Conferences

November 08, 2023

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Tops Q3 Earnings And Revenue Estimates ↗

November 07, 2023

While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

Via Talk Markets

Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript ↗

November 07, 2023

GILD earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why ↗

November 07, 2023

Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's

Via Benzinga

Gilead Sciences Announces Third Quarter 2023 Financial Results

November 07, 2023

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.